Interestingly, increase in AP1 activity has been also reported in drug-resistant cancer, suggesting that some chemotherapeutic agents can elicit AP1 activation and favor tumor cell survival by making them refractory to long-term treatments (Malorni et al., 2016; Fan et al., 2017; Liou et al., 2017). Here, FOSB is linked to cancer.